John C. Cheville

Prediction of progression after radical nephrectomy for patients with clear cell renal cell carcinoma: a stratification tool for prospective clinical trials.

The objective of the current study was to develop an algorithm to predict progression to metastases after radical nephrectomy for patients with clinically localized renal cell carcinoma (RCC) to allow stratification of patients for potential adjuvant therapy trials.

Costimulatory molecule B7‐H1 in primary and metastatic clear cell renal cell carcinoma

Cancer cell expression of costimulatory molecule B7‐H1 has been implicated as a potent inhibitor of T‐cell–mediated antitumoral immunity. The authors recently reported that B7‐H1 is aberrantly expressed in primary renal cell carcinoma (RCC). Blockade of B7‐H1, as demonstrated in several murine cancer models, now represents a promising therapeutic target in RCC. However, the potential expression of B7‐H1 in metastatic RCC has not been investigated. In the current study, the authors updated their primary RCC results with additional follow‐up and investigated the potential role of B7‐H1 in metastatic RCC.

Survival of patients with carcinoma in situ of the urinary bladder

To the authors knowledge, the long term follow‐up of patients with carcinoma in situ of the urinary bladder is limited.

Reclassification of patients with pT3 and pT4 renal cell carcinoma improves prognostic accuracy

The significance of adrenal invasion and tumor thrombus in renal cell carcinoma (RCC) has been debated recently. The authors evaluated the associations of direct adrenal invasion, perinephric fat invasion, and tumor thrombus level with outcome to determine whether reclassification would improve the prognostic accuracy of the current primary tumor classification.

Flat intraepithelial lesions of the urinary bladder

In the 1998 World Health Organization and International Society of Urologic Pathology (WHO/ISUP) classification system for bladder neoplasms, flat intraepithelial lesions of the urinary bladder were categorized as reactive atypia, atypia of unknown significance, dysplasia, and carcinoma in situ. The clinical outcomes of patients diagnosed with these atypical urothelial proliferations are uncertain.

Leiomyosarcoma of the prostate. Report of 23 cases

Background. Leiomyosarcoma of the prostate is a rare neoplasm that accounts for less than 0.1% of prostate malignancies. Previous reports of this neoplasm consisted of single case studies or small series, often combined with cases of rhabdomyosarcoma. The relationship of prognosis with histologic and immunohistochemical findings has not, to the authors knowledge, been described in a large series of cases, and the efficacy of various treatments is uncertain.

Transitional cell carcinoma of the prostate: Clinicopathologic study of 50 cases

This study was performed to identify clinical and histologic features most significant in predicting outcome in patients with transitional cell carcinoma (TCC) of the prostate without invasive bladder carcinoma.

Atypical nephrogenic metaplasia of the urinary tract: a precursor lesion?

Nephrogenic metaplasia with cytologic atypia (atypical nephrogenic metaplasia) is occasionally encountered and its biologic potential is uncertain.

Neurofibroma of the urinary bladder.

Neurofibroma of the urinary bladder is rare. Only isolated case reports have appeared. Information regarding the long term follow‐up of patients with neurofibroma is limited.

Urothelial papilloma of the bladder: Clinical and biologic implications

An international consensus has been reached regarding diagnostic criteria for papilloma of the urinary bladder. However, the incidences of recurrence and progression in patients with urothelial papilloma are uncertain.